JP7198759B2 - 弱毒化表現型を有するヒト呼吸器多核体ウイルス（ｒｓｖ）のためのワクチン候補 - Google Patents

弱毒化表現型を有するヒト呼吸器多核体ウイルス（ｒｓｖ）のためのワクチン候補 Download PDF

Info

Publication number
JP7198759B2
JP7198759B2 JP2019537752A JP2019537752A JP7198759B2 JP 7198759 B2 JP7198759 B2 JP 7198759B2 JP 2019537752 A JP2019537752 A JP 2019537752A JP 2019537752 A JP2019537752 A JP 2019537752A JP 7198759 B2 JP7198759 B2 JP 7198759B2
Authority
JP
Japan
Prior art keywords
rsv
mutations
protein
virus
genome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019537752A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019534709A (ja
JP2019534709A5 (enExample
Inventor
シリル・レヌーエン
ウルスラ・ジェイ・ブークホルツ
ピーター・エル・コリンズ
ステッフェン・ミュラー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Codagenix Inc
United States Department of Health and Human Services
Original Assignee
Codagenix Inc
United States Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Codagenix Inc, United States Department of Health and Human Services filed Critical Codagenix Inc
Publication of JP2019534709A publication Critical patent/JP2019534709A/ja
Publication of JP2019534709A5 publication Critical patent/JP2019534709A5/ja
Priority to JP2022144109A priority Critical patent/JP7573001B2/ja
Application granted granted Critical
Publication of JP7198759B2 publication Critical patent/JP7198759B2/ja
Priority to JP2024178707A priority patent/JP7862507B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/00021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/00061—Methods of inactivation or attenuation
    • C12N2760/00062—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2019537752A 2016-09-23 2017-09-22 弱毒化表現型を有するヒト呼吸器多核体ウイルス（ｒｓｖ）のためのワクチン候補 Active JP7198759B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022144109A JP7573001B2 (ja) 2016-09-23 2022-09-09 弱毒化表現型を有するヒト呼吸器多核体ウイルス（ｒｓｖ）のためのワクチン候補
JP2024178707A JP7862507B2 (ja) 2016-09-23 2024-10-11 弱毒化表現型を有するヒト呼吸器多核体ウイルス（ｒｓｖ）のためのワクチン候補

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662399133P 2016-09-23 2016-09-23
US62/399,133 2016-09-23
US201662400476P 2016-09-27 2016-09-27
US62/400,476 2016-09-27
PCT/US2017/053047 WO2018057950A1 (en) 2016-09-23 2017-09-22 Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022144109A Division JP7573001B2 (ja) 2016-09-23 2022-09-09 弱毒化表現型を有するヒト呼吸器多核体ウイルス（ｒｓｖ）のためのワクチン候補

Publications (3)

Publication Number Publication Date
JP2019534709A JP2019534709A (ja) 2019-12-05
JP2019534709A5 JP2019534709A5 (enExample) 2020-10-08
JP7198759B2 true JP7198759B2 (ja) 2023-01-04

Family

ID=60009756

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019537752A Active JP7198759B2 (ja) 2016-09-23 2017-09-22 弱毒化表現型を有するヒト呼吸器多核体ウイルス（ｒｓｖ）のためのワクチン候補
JP2022144109A Active JP7573001B2 (ja) 2016-09-23 2022-09-09 弱毒化表現型を有するヒト呼吸器多核体ウイルス（ｒｓｖ）のためのワクチン候補
JP2024178707A Active JP7862507B2 (ja) 2016-09-23 2024-10-11 弱毒化表現型を有するヒト呼吸器多核体ウイルス（ｒｓｖ）のためのワクチン候補

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022144109A Active JP7573001B2 (ja) 2016-09-23 2022-09-09 弱毒化表現型を有するヒト呼吸器多核体ウイルス（ｒｓｖ）のためのワクチン候補
JP2024178707A Active JP7862507B2 (ja) 2016-09-23 2024-10-11 弱毒化表現型を有するヒト呼吸器多核体ウイルス（ｒｓｖ）のためのワクチン候補

Country Status (5)

Country Link
US (4) US10808012B2 (enExample)
EP (1) EP3515930A1 (enExample)
JP (3) JP7198759B2 (enExample)
AU (5) AU2017332789B2 (enExample)
WO (1) WO2018057950A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2900713A1 (en) 2013-02-08 2014-08-14 Steffen Mueller Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization
AU2017332789B2 (en) 2016-09-23 2021-05-27 Codagenix, Inc. Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes
JP2021508696A (ja) 2017-12-22 2021-03-11 コーダ−ジェニックス・インコーポレイテッドＣｏｄａ−Ｇｅｎｉｘ， Ｉｎｃ． がん処置のためのコドン対脱最適化領域を有する組換え型ウイルス及びその使用法
WO2019172982A1 (en) 2018-03-08 2019-09-12 Codagenix Inc. Attenuated flaviviruses
WO2021231767A1 (en) 2020-05-13 2021-11-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Rsv vaccine bearing one or more p gene mutations
WO2022011428A1 (en) * 2020-07-16 2022-01-20 Griffith University Live-attenuated virus vaccine
AU2022254738A1 (en) * 2021-04-08 2023-09-07 Codagenix Inc. Method of eliciting an immune response against respiratory syncytial virus
WO2025054424A1 (en) * 2023-09-06 2025-03-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human parainfluenza virus immunogenic molecules
WO2025128971A1 (en) * 2023-12-14 2025-06-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Rsv vaccine bearing a polynucleotide which is de-optimised and de-attenuated

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150368622A1 (en) 2013-02-08 2015-12-24 The United Of America, As Represented By Secretary, Department Of Health And Human Services Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3224404A1 (de) 1982-06-30 1984-01-05 LuK Lamellen und Kupplungsbau GmbH, 7580 Bühl Reibungskupplung sowie verfahren zu deren montage
US6264957B1 (en) 1995-09-27 2001-07-24 The United States Of America As Represented By The Department Of Health And Human Services Product of infectious respiratory syncytial virus from cloned nucleotide sequences
EP0912724B1 (en) 1996-07-15 2009-12-09 The Government of The United States of America, as represented by The Department of Health and Human Services Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
DE69842165D1 (de) 1997-05-23 2011-04-21 Us Of America As Represented By The Secretary Of The Dept Of Health And Human Services Herstellung attenuierter parainfluenza-virus impfstoffe aus klonierten nukleotidsequenzen
JP2002541785A (ja) 1999-04-13 2002-12-10 アメリカ合衆国 クローン化ヌクレオチド配列からの弱毒化キメラ呼吸系発疹ウイルスワクチンの製造
US20040161846A1 (en) 2000-11-22 2004-08-19 Mason Anthony John Method of expression and agents identified thereby
WO2006085987A2 (en) 2004-07-09 2006-08-17 University Of Iowa Research Foundation Rna interference in respiratory epitheial cells
EP2808384B1 (en) 2004-10-08 2017-12-06 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Modulation of replicative fitness by using less frequently used synonymous codons
PL2139515T5 (pl) 2007-03-30 2024-04-08 The Research Foundation Of The State University Of New York Atenuowane wirusy przydatne w szczepionkach
BRPI0921424A2 (pt) 2008-11-05 2016-01-05 Merck Sharp & Dohme vírus sincicial respiratório atenuado, composição imunogênica, molécula de ácido nucléico, célula recombinante, método para produzir uma resposta imune protetiva em um paciente, e, uso de uma quantidade imunologicamente eficaz de um ou mais dos seguintes: um rsv atenuado, uma população de rsv atenuado e uma composição imunogênica.
US10227569B2 (en) 2011-04-12 2019-03-12 Emory University Respiratory syncytial virus expression vectors
AU2017332789B2 (en) 2016-09-23 2021-05-27 Codagenix, Inc. Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150368622A1 (en) 2013-02-08 2015-12-24 The United Of America, As Represented By Secretary, Department Of Health And Human Services Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization

Also Published As

Publication number Publication date
JP2022188047A (ja) 2022-12-20
US20210188920A1 (en) 2021-06-24
JP2019534709A (ja) 2019-12-05
AU2021218112A1 (en) 2021-09-09
US11390651B2 (en) 2022-07-19
AU2017332789A1 (en) 2019-05-09
AU2021218112B2 (en) 2022-07-21
JP7862507B2 (ja) 2026-05-19
JP2025020142A (ja) 2025-02-12
US20220340619A1 (en) 2022-10-27
AU2024203948B2 (en) 2026-02-05
WO2018057950A1 (en) 2018-03-29
AU2026203425A1 (en) 2026-05-21
JP7573001B2 (ja) 2024-10-24
AU2024203948A1 (en) 2024-07-04
US20240417431A1 (en) 2024-12-19
AU2017332789B2 (en) 2021-05-27
US10808012B2 (en) 2020-10-20
EP3515930A1 (en) 2019-07-31
AU2022256195A1 (en) 2023-02-02
AU2022256195B2 (en) 2024-03-14
US12054519B2 (en) 2024-08-06
US20190233476A1 (en) 2019-08-01

Similar Documents

Publication Publication Date Title
JP7573001B2 (ja) 弱毒化表現型を有するヒト呼吸器多核体ウイルス（ｒｓｖ）のためのワクチン候補
US12054749B2 (en) Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization
JP7357709B2 (ja) さまざまな弱毒化表現型をもたらすｍ２－２ ｏｒｆにおける突然変異を含む組換えｒｓウイルス株
US11918638B2 (en) Recombinant respiratory syncytial virus strains comprising NS1 and NS2 gene shifts
RU2773746C2 (ru) Рекомбинантные штаммы респираторно-синцитиального вируса с мутациями в м2-2 orf, обеспечивающими диапазон аттенуирующих фенотипов
BR112018011674B1 (pt) Vírus sincicial respitatório (rsv) recombinante, seu método de produção, seus usos, bem como molécula de polinucleotídeo isolada, vetor e composição farmacêutica

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200828

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200828

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210629

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210630

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210928

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220909

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220909

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220930

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221004

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221122

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221219

R150 Certificate of patent or registration of utility model

Ref document number: 7198759

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250